About Dr Nwulia
About Dr Nwulia
Founder & Chief Excecutive Officer
Dr. Evaristus Nwulia
Founder & CEO Evon Medics Inc.
Professor of Neuropsychiatry, Howard University
Director, Blueprint NeuroTech Incubator Seedling Program
Multi-Principal Investigator, Neurotech Harbor
Before I was a founder, I was a grandson.
My grandfather, who was very close to me, suffered from Alzheimer’s disease. I watched a strong, dignified man slowly lose pieces of himself. First it was his short-term memory. Later, his stories. Then his independence. And eventually, the very essence of himself.
Alzheimer’s disease does not just affect the person diagnosed. It rewrites the emotional history of an entire family. It forces children to become caregivers. It turns familiar faces into unfamiliar ones. It replaces conversation with confusion.
As a physician, I kept asking myself one question: could we have done something earlier — before the damage became irreversible, before the hippocampus starts to shrink, before the memories began to disappear?
Could we have done something earlier — before the damage became irreversible, before the memories began to disappear?
Reacting Later, or Training Earlier.
For decades, Alzheimer’s disease was treated as something we react to — after symptoms appear, after cognitive decline has begun, after neurodegeneration has already taken hold.
But the science has changed. We now understand that the earliest structural changes in Alzheimer’s disease occur in the medial temporal lobe — the hippocampus and entorhinal cortex — the very circuits responsible for short-term memory and spatial navigation, for finding your way through familiar and unfamiliar places alike.
And we know something else: these regions are not static. They are plastic. They adapt. They respond to stimulation. Professional taxi drivers who spend years navigating complex city streets develop larger posterior hippocampi — navigation is not just transportation, it’s a brain exercise. Driving patterns can even reveal subtle cognitive decline years before a formal Alzheimer’s diagnosis.
In a recent clinical trial of our own computerized olfactory training program, targeted stimulation of these medial temporal regions improved cognition scores and increased hippocampal and entorhinal cortex volume after sustained training in people with mild cognitive impairment.
Alzheimer’s disease causes these regions to shrink. Sustained, targeted stimulation helps them rebuild. That is the new frontier — not reacting to Alzheimer’s disease, but training the brain before decline begins, and before it accelerates.
Hippocampus
Central to short-term memory formation. One of the first regions Alzheimer’s disease targets — and, in our trial, one of the first to show volume increases after training.
Entorhinal cortex
A gateway between the hippocampus and the rest of the brain, critical for spatial navigation. Also showed measurable volume increases after sustained stimulation.
Why it matters
These regions are plastic, not fixed. That single fact reframes Alzheimer’s from an inevitability into something that may be trainable against, years before diagnosis.
Why we founded Evon Medics.
Evon Medics Inc. was built on one core belief: that the brain can be trained — and that this training must be accessible, scalable, affordable, and grounded in solid neuroscience. We are a neurotechnology company. Our mission is to convert decades of neuroscience research into practical, everyday tools that empower people to take charge of their brain health long before crisis strikes.